Evidence map›Paper›PMID 29476136›Full record

ArticleNature communications2018

A recurrent kinase domain mutation in PRKCA defines chordoid glioma of the third ventricle.

Benjamin Goode, Gourish Mondal, Michael Hyun, Diego Garrido Ruiz, Yu-Hsiu Lin, Jessica Van Ziffle, Nancy M Joseph, Courtney Onodera, Eric Talevich, James P Grenert and 19 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed, 2 pooled it
6.0field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

43 citing papers in PubMed, 2 syntheses or guidelines pooled it, 76 citations in OpenAlex.

  1. Pooled it
  2. Molecular features in gangliogliomas: a systematic review.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2026
    Pooled it
  3. Article
  4. A Genomically Tailored Multiagent Precision Medicine Clinical Trial for Adults with Recurrent Glioblastoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  5. Review
  6. The chordoid gliomaScience signaling · 2025
    Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Molecular markers for pediatric low-grade glioma.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2024
    Review
  13. Glioma.Nature reviews. Disease primers · 2024
    Review
  14. Article
  15. Review
  16. Benign Glioma.Advances in experimental medicine and biology · 2023
    Article
  17. Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 10 institutions in 2 countries.

Benjamin GoodeDepartment of Pathology, University of California, San Francisco, CA, 94143, USA.
Gourish MondalDepartment of Pathology, University of California, San Francisco, CA, 94143, USA.
Michael HyunDepartment of Pathology, University of California, San Francisco, CA, 94143, USA.
Diego Garrido RuizDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0002-2441-385X
Yu-Hsiu LinDepartment of Laboratory Medicine, University of California, San Francisco, CA, 94107, USA.
Jessica Van ZiffleDepartment of Pathology, University of California, San Francisco, CA, 94143, USA.
Nancy M JosephDepartment of Pathology, University of California, San Francisco, CA, 94143, USA.
Courtney OnoderaClinical Cancer Genomics Laboratory, University of California, San Francisco, CA, 94115, USA.
Eric TalevichClinical Cancer Genomics Laboratory, University of California, San Francisco, CA, 94115, USA.
James P GrenertDepartment of Pathology, University of California, San Francisco, CA, 94143, USA.
Iman H HewediDepartment of Pathology, Faculty of Medicine, Ain Shams University, Cairo, 11591, Egypt.
Matija SnuderlDepartments of Pathology and Neurology, NYU Langone Medical Center, New York, NY, 10016, USA.
Daniel J BratDepartment of Pathology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
Bette K Kleinschmidt-DeMastersDepartment of Pathology, University of Colorado at Denver, Aurora, CO, 80045, USA.
Fausto J RodriguezDepartment of Pathology, Johns Hopkins University School of Medicine, Baltimore, MD, 21287, USA.ORCID http://orcid.org/0000-0001-8662-1219
David N LouisDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, 02114, USA.
William H YongDepartment of Pathology, David Geffen School of Medicine, University of California, Los Angeles, CA, 90095, USA.
M Beatriz LopesDepartment of Pathology, University of Virginia School of Medicine, Charlottesville, VA, 22908, USA.
Marc K RosenblumDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, 10065, USA.
Nicholas ButowskiDepartment of Neurological Surgery, University of California, San Francisco, CA, 94143, USA.
Tarik TihanDepartment of Pathology, University of California, San Francisco, CA, 94143, USA.
Andrew W BollenDepartment of Pathology, University of California, San Francisco, CA, 94143, USA.
Joanna J PhillipsDepartment of Pathology, University of California, San Francisco, CA, 94143, USA.
Arun P WiitaDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, 94158, USA.ORCID http://orcid.org/0000-0002-7465-6964
Iwei YehDepartment of Pathology, University of California, San Francisco, CA, 94143, USA.
Matthew P JacobsonDepartment of Pharmaceutical Chemistry, University of California, San Francisco, CA, 94158, USA.
Boris C BastianDepartment of Pathology, University of California, San Francisco, CA, 94143, USA.
Arie PerryDepartment of Pathology, University of California, San Francisco, CA, 94143, USA.ORCID http://orcid.org/0000-0002-8300-7261
David A SolomonDepartment of Pathology, University of California, San Francisco, CA, 94143, USA. david.solomon@ucsf.edu.ORCID http://orcid.org/0000-0003-4571-7999
University of California, San Francisco · USAin Shams University · EGHarvard University · USJohns Hopkins University · USMemorial Sloan Kettering Cancer Center · USNorthwestern University · USNYU Langone Health · USUniversity of California, Los Angeles · USUniversity of Colorado Denver · USUniversity of Virginia · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
Tissue CoreP50CA097257 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Joseph F Costello · 2002 to 2026
$57.4M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI David A. Nathanson · 2017 to 2026
$25.2M
Cohesin gene mutations in tumorigenesisDP5OD021403 · OD · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI SOLOMON, DAVID A. · 2015 to 2019
$2.0M
Global Assessment of Myeloma Response to ChemotherapyK08CA184116 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI WIITA, ARUN P. · 2014 to 2018
$684k
NCI NIH HHS K08 CA184116NCI NIH HHS P30 CA008748NCI NIH HHS P50 CA097257NCI NIH HHS P50 CA211015NIH HHS DP5 OD021403
6 · The paper itself

Abstract

Chordoid glioma is a rare brain tumor thought to arise from specialized glial cells of the lamina terminalis along the anterior wall of the third ventricle. Despite being histologically low-grade, chordoid gliomas are often associated with poor outcome, as their stereotypic location in the third ventricle makes resection challenging and efficacious adjuvant therapies have not been developed. Here we performed genomic profiling on 13 chordoid gliomas and identified a recurrent D463H missense mutation in PRKCA in all tumors, which localizes in the kinase domain of the encoded protein kinase C alpha (PKCα). Expression of mutant PRKCA in immortalized human astrocytes led to increased phospho-ERK and anchorage-independent growth that could be blocked by MEK inhibition. These studies define PRKCA as a recurrently mutated oncogene in human cancer and identify a potential therapeutic vulnerability in this uncommon brain tumor.

Indexed as

AdultAgedCerebral Ventricle NeoplasmsExtracellular Signal-Regulated MAP KinasesFemaleGliomaHumansMaleMiddle AgedMutation, MissensePhosphorylationProtein DomainsProtein Kinase C-alphaThird VentricleExtracellular Signal-Regulated MAP KinasesPRKCA protein, humanProtein Kinase C-alpha

Identifiers

PMID29476136
PMCPMC5824822
OpenAlexW2799789512

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.